Showing 2551-2560 of 7016 results for "".
Risk-Adapted Screening Offers Viable Alternative for Colorectal Cancer
https://reachmd.com/programs/clinicians-roundtable/risk-adapted-screening-colorectal-cancer-alternative/56444/BCMA mRNA CAR-T Shows Durable Benefit in MG
https://reachmd.com/programs/neurofrontiers/bcma-mrna-car-t-shows-durable-benefit-in-mg/51012/Defining the Challenge in Complex Cases of Psoriatic Arthritis
https://reachmd.com/programs/living-rheum/complex-psoriatic-arthritis-cases/54445/Managing psoriatic arthritis gets more complex when patients don’t respond to standard treatments or present with overlapping conditions. Hear Dr. Laura Coates' insights on difficult-to-treat and complex-to-manage psoriatic arthritis—highlighting how clear classification can guide more targeted therMechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
https://reachmd.com/programs/cme/mechanistic-evolution-in-ras-therapy-on-state-and-multi-selective-targeting/54120/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer
https://reachmd.com/programs/cme/unmet-need-second-line-outcomes-remain-poor-for-nsclc-and-pancreatic-cancer/54118/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.LUMINESCE: Assessing Satralizumab in Generalized Myasthenia Gravis
https://reachmd.com/programs/neurofrontiers/luminesce-assessing-satralizumab-in-generalized-myasthenia-gravis/32857/Cohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
https://reachmd.com/clinical-practice/oncology-hematology/cohort-9-of-the-phase-2-ev-202-trial-first-line-enfortumab-vedotin-plus-pembrolizumab-in-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma/39779/In cohort 9 of EV-202, first-line enfortumab vedotin plus pembrolizumab showed promising and durable responses in patients with recurrent or metastatic HNSCC.Early Rituximab Use in Sjögren’s Syndrome: A Meta-Analysis Review
https://reachmd.com/programs/living-rheum/early-rituximab-use-in-sjogrens-syndrome-a-meta-analysis-review/36343/Targeting CCR4 in CAR-Associated Peripheral T-Cell Lymphoma
https://reachmd.com/programs/project-oncology/targeting-ccr4-in-car-associated-peripheral-t-cell-lymphoma/37205/Updates from MINT: Inebilizumab Reduces Relapses and Rescue Therapy Use
https://reachmd.com/programs/neurofrontiers/updates-from-mint-inebilizumab-reduces-relapses-and-rescue-therapy-use/35869/After the primary findings from the Myasthenia Gravis Inebilizumab Trial (MINT) demonstrated the clinical benefit and safety of inebilizumab for patients with generalized myasthenia gravis (gMG), a secondary analysis evaluated inebilizumab’s impact on exacerbation rates and the need for rescue thera